• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYInsights
  • MYBoard
  • Strategy & Consulting
Select Page

On the threshold of a possible cure: innovations in treating multiple myeloma

by | Jun 9, 2024 | Publications

Orv Hetil. 2024 Jun 9;165(23):891-899. doi: 10.1556/650.2024.33036. Print 2024 Jun 9. ABSTRACT A myeloma multiplex diagnosztikája és kezelése terén jelentős előrelépések történtek az elmúlt évek során. Az immunmoduláns ágensek, a proteaszómagátlók és a nagy dózisú...

Improvement of daratumumab- or elotuzumab-mediated NK cell activity by the bi-specific 4-1BB agonist, DARPin alpha-FAPx4-1BB: A preclinical study in multiple myeloma

by | Jun 9, 2024 | Publications

Biomed Pharmacother. 2024 Jun 7;176:116877. doi: 10.1016/j.biopha.2024.116877. Online ahead of print. ABSTRACT Multiple myeloma (MM) progression is closely dependent on cells in the bone marrow (BM) microenvironment, including fibroblasts (FBs) and immune cells. In...

Endothelial injury and dysfunction with emerging immunotherapies in multiple myeloma, the impact of COVID-19, and endothelial protection with a focus on the evolving role of defibrotide

by | Jun 9, 2024 | Publications

Blood Rev. 2024 Jun 3:101218. doi: 10.1016/j.blre.2024.101218. Online ahead of print. ABSTRACT Patients with multiple myeloma (MM) were among the groups impacted more severely by the COVID-19 pandemic, with higher rates of severe disease and COVID-19-related...

Response adaptive salvage treatment with daratumumab-lenalidomide-dexamethasone for newly diagnosed transplant-eligible multiple myeloma patients failing front-line bortezomib-based induction therapy-ALLG MM21

by | Jun 9, 2024 | Publications

Br J Haematol. 2024 Jun 8. doi: 10.1111/bjh.19578. Online ahead of print. ABSTRACT In Australia, bortezomib-based induction (V-IND) is used in >90% of newly diagnosed transplant-eligible multiple myeloma (MM) patients. Four cycles of V-IND with...

Effect of human bone marrow mesenchymal stem cell-derived microvesicles on the apoptosis of the multiple myeloma cell line U266

by | Jun 9, 2024 | Publications

J Cancer Res Clin Oncol. 2024 Jun 8;150(6):299. doi: 10.1007/s00432-024-05822-2. ABSTRACT BACKGROUND: Microvesicles are membraned particles produced by different types of cells recently investigated for anticancer purposes. The current study aimed to investigate the...

Anti-tumor effect of dandelion flavone on multiple myeloma cells and its mechanism

by | Jun 9, 2024 | Publications

Discov Oncol. 2024 Jun 8;15(1):215. doi: 10.1007/s12672-024-01076-z. ABSTRACT BACKGROUND: Multiple myeloma (MM) is a prevalent hematologic malignancy characterized by the uncontrolled proliferation of monoclonal plasma cells in the bone marrow and excessive monoclonal...
« Older Entries
Next Entries »

Recent Content

  • (no title)
  • Efficacy of novel therapies for refractory and relapsed multiple myeloma in China: A scoping systematic review
  • Cytomegalovirus reactivation during treatment with bispecific antibodies for relapsed/refractory multiple myeloma
  • Cytomegalovirus reactivation during treatment with bispecific antibodies for relapsed/refractory multiple myeloma
  • (no title)
  • Correction: Activity of CAR-T cells and bispecific antibodies in multiple myeloma with extramedullary involvement
  • Sex-specific dysregulation of exosomal non-coding RNAs drives multiple myeloma progression
  • (no title)
  • (no title)
  • Multi-cohort high-dimensional proteomics reveals early risk markers for lymphoid cancer subtypes
  • Facebook
  • X
  • Instagram
©2016-2025 MYELOMA360 & Connect BioMed
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT